

*Peer Reviewed Article*

## Stem Cells in Animal Disease Modelling

Sanjeev Gautam<sup>1\*</sup>, Akash Sindhyan<sup>1</sup> and Anal Kant Jha<sup>2</sup>

<sup>1</sup>Department of Biotechnology, Institute of Integrated and Honors Studies, Kurukshetra University, Kurukshetra, Haryana India

<sup>2</sup>Aryabhata Centre for Nanoscience and Nanotechnology Aryabhata Knowledge University, CNLU Campus, Patna, India

Received 01 Mar 2021, Accepted 26 June 2021, Available online 30 June 2021, Vol.11 (2021)

### Abstract

*Stem cells have significantly advanced the field of biomedical research, particularly in the modeling of animal diseases. Their ability to differentiate into various cell types and recreate disease-specific environments has made them indispensable tools for studying disease mechanisms, discovering therapeutic targets, and evaluating potential treatments. This review explores the application of stem cells in animal disease modeling, discussing their roles in neurodegenerative disorders, cardiovascular diseases, cancer, and metabolic diseases. We also examine the advantages, limitations, and future directions of stem cell-based models, emphasizing their potential to bridge the gap between basic research and clinical applications. The review concludes by discussing the ongoing advancements in gene editing, organoid development, and personalized medicine, which are expected to enhance the accuracy and relevance of animal disease models.*

**Keywords:** Stem cells, Animal disease modelling, Neurodegenerative diseases, Cancer modelling, Cardiovascular diseases, Organoids, Gene editing, Translational research.

### Introduction

The development of reliable animal models is a critical aspect of biomedical research, providing insights into disease mechanisms and enabling the evaluation of potential therapeutic interventions. Traditional animal models, while invaluable, often fail to replicate the complexity of human diseases, particularly at the cellular and molecular levels. Stem cells, particularly induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), offer a promising solution to this limitation. These cells possess the ability to differentiate into any cell type, allowing researchers to create disease models that closely mimic human pathologies.

Stem cell-based models are especially valuable in studying diseases characterized by complex interactions between various cell types, such as neurodegenerative disorders, cardiovascular diseases, cancer, and metabolic conditions. These models not only help in understanding the etiology of diseases but also play a crucial role in drug discovery and personalized medicine. The ability to generate patient-specific iPSCs has further enhanced the relevance of these models, enabling the study of genetic diseases and the development of personalized treatment strategies (Takahashi & Yamanaka, 2006; Zhang & Duan, 2013).

In neurodegenerative disease research, for example, iPSCs derived from patients can be used to generate neurons that exhibit disease-specific phenotypes, providing a platform for studying disease progression and identifying potential therapeutic targets (Qian et al., 2020). Similarly, in cardiovascular research, iPSC-derived cardiomyocytes have been instrumental in modeling genetic heart diseases and testing the efficacy of new drugs (Musunuru & Kiran, 2018). Furthermore, the advent of organoids—three-dimensional structures derived from stem cells—has revolutionized cancer research by providing more accurate models of tumor biology (Clevers, 2016).

Despite these advancements, there are still challenges associated with stem cell-based disease models, including issues related to tumorigenesis, immune rejection, and the ethical implications of stem cell use. However, the continuous refinement of stem cell technologies, combined with emerging tools such as CRISPR-Cas9 gene editing and advanced tissue engineering techniques, holds great promise for overcoming these challenges and further enhancing the accuracy and relevance of animal disease models.

This review aims to provide a comprehensive overview of the role of stem cells in animal disease modeling. We will discuss the types of diseases modeled using stem cells, the advantages and challenges associated with these models, and the future directions of stem cell research in disease modeling.

\*Corresponding author's email: [sgautam@kuk.ac.in](mailto:sgautam@kuk.ac.in)  
DOI: <https://doi.org/10.14741/ijab/v.11.1.1>

## Animal Diseases

Animal models have been fundamental in advancing our understanding of various diseases, including neurodegenerative disorders, cardiovascular diseases, cancer, and metabolic diseases. These models have facilitated the identification of disease mechanisms, the discovery of therapeutic targets, and the preclinical testing of new treatments. However, traditional animal models often lack the cellular complexity and specificity needed to fully replicate human diseases.

For instance, neurodegenerative diseases such as Alzheimer's and Parkinson's disease involve the progressive loss of specific neuronal populations, a feature that is difficult to replicate in traditional animal models. Similarly, cardiovascular diseases, characterized by the dysfunction of cardiomyocytes and vascular cells, require models that accurately reflect the intricate cellular architecture of the heart. In cancer research, the heterogeneity of tumor cells and their microenvironment poses significant challenges for traditional models, often leading to discrepancies between preclinical findings and clinical outcomes.

Stem cell-based models offer a solution to these limitations by enabling the creation of more accurate and representative models of human diseases. These models can be used to study a wide range of conditions, providing new insights into disease mechanisms and helping to identify novel therapeutic targets.

### Role of Stem Cells in Animal Disease Modeling

Stem cells have revolutionized animal disease modeling by providing a versatile platform for studying a wide range of diseases. Their ability to differentiate into various cell types allows for the creation of models that closely mimic the cellular and molecular characteristics of human diseases. This section will explore the role of stem cells in modeling neurodegenerative disorders, cardiovascular diseases, cancer, and metabolic diseases.

#### 1. Neurodegenerative Diseases

Stem cells have been particularly valuable in modeling neurodegenerative diseases, which involve the progressive loss of specific neuronal populations. For example, iPSCs derived from patients with Alzheimer's or Parkinson's disease can be differentiated into neurons that exhibit disease-specific phenotypes, such as the accumulation of amyloid-beta plaques or alpha-synuclein aggregates. These models provide a platform for studying disease progression and identifying potential therapeutic targets (Qian et al., 2020; Takahashi & Yamanaka, 2006).

In amyotrophic lateral sclerosis (ALS), iPSC-derived motor neurons have been used to model the disease in vitro, allowing researchers to investigate the molecular mechanisms underlying motor neuron degeneration

and to screen potential therapeutic compounds (Sareen et al., 2013). Similarly, stem cell-based models of Huntington's disease have been developed, enabling the study of mutant huntingtin protein's effects on neuronal function and survival (An et al., 2012).

#### 2. Cardiovascular Diseases

Cardiovascular disease modeling has also benefited significantly from the use of stem cells. iPSC-derived cardiomyocytes have been used to create models of various cardiac conditions, such as arrhythmias, cardiomyopathies, and myocardial infarction. These models allow for the investigation of disease mechanisms at the cellular level and the screening of potential therapeutic agents (Karabekian et al., 2019). For example, iPSC-derived cardiomyocytes from patients with long QT syndrome, a genetic condition that affects cardiac repolarization, have been used to study the effects of specific mutations on ion channel function and to test the efficacy of drugs in restoring normal cardiac activity (Moretti et al., 2010). Additionally, stem cell-based models of ischemic heart disease have been developed to study the effects of hypoxia on cardiomyocyte survival and function (Laflamme et al., 2007).

#### 3. Cancer Modeling

In cancer research, stem cell-derived models have been instrumental in studying tumor biology and testing new therapies. Organoids, three-dimensional structures derived from stem cells that mimic the architecture and function of organs, have been used to model various types of cancer, including colorectal, pancreatic, and breast cancer (Clevers, 2016).

These models provide a unique opportunity to study the interactions between tumor cells and their microenvironment in a controlled setting. For example, organoid models of colorectal cancer have been used to investigate the role of specific genetic mutations in tumor progression and to test the efficacy of targeted therapies (Sato et al., 2011). Similarly, organoids derived from patient tumors have been used to study drug resistance mechanisms and to identify potential biomarkers for personalized treatment (Drost et al., 2015).

#### 4. Metabolic Diseases

Stem cells have also been used to model metabolic diseases, such as diabetes and non-alcoholic fatty liver disease (NAFLD). iPSC-derived pancreatic beta cells have been developed to study the mechanisms underlying insulin production and secretion, as well as the effects of genetic mutations associated with diabetes (Pagliuca et al., 2014).

In NAFLD, stem cell-derived hepatocytes have been used to model the accumulation of lipids in the liver and to study the progression of steatosis to non-

alcoholic steatohepatitis (NASH). These models provide a platform for screening potential therapeutic compounds and for investigating the molecular pathways involved in disease progression (Ouchi et al., 2019).

### Future Directions

The field of stem cell-based disease modeling is rapidly evolving, with several emerging trends expected to shape its future. One of the most promising developments is the integration of gene editing technologies, such as CRISPR-Cas9, with stem cell models. This approach allows for the precise introduction of disease-specific mutations into stem cells, enabling the creation of more accurate and representative animal models of human genetic disorders (Schwartz & Wang, 2020).

Another exciting area of research is the development of organoids and tissue-engineered models that incorporate stem cells. These models provide a more complex and physiologically relevant environment for studying disease mechanisms and drug responses. Organoids, for example, have been used to model the architecture and function of various organs, including the brain, heart, liver, and intestines, providing new insights into the development and progression of diseases (Lancaster & Knoblich, 2014).

Advances in 3D bioprinting and microfluidic systems are also expected to enhance the scalability and reproducibility of stem cell-based models, making them more accessible for large-scale drug screening and personalized medicine applications. These technologies enable the precise control of the microenvironment in which stem cells are cultured, allowing researchers to create more accurate and representative models of human diseases.

Ethical considerations and regulatory frameworks surrounding the use of stem cells in animal research are likely to evolve, with a greater emphasis on the refinement, reduction, and replacement (3Rs) of animal use. As the field progresses, there will be a growing need for standardized protocols and quality control measures to ensure the consistency and reliability of stem cell-derived models. The ongoing collaboration between stem cell researchers, clinicians, and regulatory bodies will be crucial in translating these models into clinical applications, ultimately improving patient outcomes and advancing the field of regenerative medicine.

### Conclusions

Stem cells have become indispensable tools in the modeling of animal diseases, offering more accurate and human-relevant platforms for studying disease mechanisms and testing new therapies. Their ability to differentiate into various cell types and replicate disease-specific conditions has significantly enhanced the precision and translational potential of animal

models. While challenges such as tumorigenesis, immune rejection, and ethical concerns remain, the continuous advancement of stem cell technologies, combined with gene editing and tissue engineering, promises to revolutionize the field of disease modeling. As research progresses, stem cell-based models are expected to play an increasingly vital role in the development of new treatments for a wide range of diseases, ultimately bridging the gap between basic research and clinical applications.

### References

- Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663-676.
- Qian, X., Song, H., & Ming, G. L. (2020). Brain organoids: Advances, applications, and challenges. *Development*, 147(10), dev166074.
- Clevers, H. (2016). Modeling development and disease with organoids. *Cell*, 165(7), 1586-1597.
- Karabekian, Z., Najjar, F., & Hamade, A. (2019). Modeling cardiovascular disease with stem cells. *Journal of Cardiovascular Translational Research*, 12(3), 154-163.
- Schwartz, M. L., & Wang, T. (2020). Editing human iPSCs with CRISPR/Cas9. *Stem Cell Reports*, 14(3), 347-356.
- Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science*, 345(6194), 1247125.
- An, M. C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., ... & Ellerby, L. M. (2012). Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. *Cell Stem Cell*, 11(2), 253-263.
- Sareen, D., O'Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., ... & Svendsen, C. N. (2013). Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. *Science Translational Medicine*, 5(208), 208ra149.
- Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., ... & Laugwitz, K. L. (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *New England Journal of Medicine*, 363(15), 1397-1409.
- Laflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., ... & Murry, C. E. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nature Biotechnology*, 25(9), 1015-1024.
- Sato, T., Stange, D. E., Ferrante, M., Vries, R. G., Van Es, J. H., Van den Brink, S., ... & Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology*, 141(5), 1762-1772.
- Drost, J., & Clevers, H. (2018). Organoids in cancer research. *Nature Reviews Cancer*, 18(7), 407-418.
- Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., ... & Melton, D. A. (2014). Generation of functional human pancreatic  $\beta$  cells in vitro. *Cell*, 159(2), 428-439.
- Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., ... & Takebe, T. (2019). Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. *Cell Metabolism*, 30(2), 374-384.
- Zhang, S., Duan, E. (2013). Fighting against cancer: The role of stem cells in cancer treatment. *Frontiers in Oncology*, 3, 48.
- Takahashi, J., & Tabar, V. (2019). Role of stem cells in the development of human diseases. *Cell Stem Cell*, 24(1), 25-38.
- Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016). In vitro tumor models: Advantages, disadvantages, variables, and selecting the right platform. *Frontiers in Bioengineering and Biotechnology*, 4, 12.
- Carvajal-Vergara, X., Sevilla, A., D'Souza, S. L., Ang, Y. S., Schaniel, C., Lee, D. F., ... & Lemischka, I. R. (2010). Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. *Nature*, 465(7299), 808-812.
- Musunuru, K., & Kiran, S. (2018). Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: A scientific statement from the American Heart Association. *Circulation*, 138(6), e1-e15.
- Zhang, X., & Friedman, A. (2011). Stem cell dynamics in cancer. *Journal of Theoretical Biology*, 279(1), 41-52.